North America leads rapidly growing GLP-1 market
The US drives growth via branded therapies, rising obesity, and broader use in diabetes and weight management.
GLP-1s
PRI report warns of risks tied to unauthorized GLP-1 knockoffs
A new Pacific Research Institute report warns that unauthorized compounded GLP-1 drugs may pose patient safety risks and hinder future pharmaceutical innovation.
GLP-1 boom fuels whey protein shortage concerns
Record whey protein prices and tightening supplies highlight the ripple effects of growing GLP-1 adoption across the health and nutrition marketplace.
NACDS updates members on CMS Medicare GLP-1 Bridge Program rollout
NACDS is advising chain pharmacy members on the upcoming launch of the CMS Medicare GLP-1 Bridge Program, a temporary demonstration that will provide eligible Medicare beneficiaries with access to certain medications beginning July 1.
Employers wary of GLP-1 costs
Other new research, from Acosta Group, reveals that GLP-1s are reshaping consumer behavior including lifestyle, health and wellness, and personal care choices.
GLP-1 hydration market to reach $6 billion by 2036
Hydration products designed for GLP-1 medication users are a fast-growing category across wellness and pharmacy channels, driven by demand for low-sugar, digestive-friendly options.
Coffee Chat: Meg Rand, Acosta Group
GLP-1 users drive trends across range of product segments.
Harris Teeter expands GLP-1 access
Regional grocer integrates medications, dietitians and affordability tools to support weight management.
GLP-1 access expands with launch of oral Ozempic
Novo Nordisk is launching a pill form of Ozempic, offering a new option for type 2 diabetes and positioning pharmacies at the forefront of access, adherence, and the growing GLP-1 demand.
U.S. prescription drug spending on track to exceed $1 trillion
Weight-loss drugs drive historic growth in 2025.
GLP-1 ‘halo effect’ accelerates health-driven purchasing trends
New Acosta Group research shows GLP-1 users are driving shifts toward healthier eating, targeted wellness and new retail opportunities.
FDA approves Lilly’s Foundayo, first unrestricted GLP-1 pill
Oral GLP-1 therapy achieves double-digit weight loss in trials and launches this month with no food or water restrictions, expanding access through retail and direct-to-consumer channels.
Kroger pharmacies add Zepbound KwikPen
“Our customers and communities want affordable, effective weight-management treatment options with real affordability,” said Colleen Lindholz, group vice president and president of Kroger Health.
Zepbound’s growth fuels new employer coverage models
The success of Eli Lilly’s Zepbound is encouraging efforts to expand access to obesity treatments by clarifying pricing and reducing costs.
Amazon Pharmacy expands access to Eli Lilly’s Zepbound KwikPen for weight management
Now offering customers transparent cash-pay pricing starting at $299 per month for the 2.5 mg KwikPen starter dose and convenient, fast home delivery.
Walgreens Virtual Healthcare adds weight management services
Patients can access weight management care for $49 per visit, no monthly subscription needed.